首页> 美国卫生研究院文献>Journal of Virology >Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20)
【2h】

Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20)

机译:抗恩夫韦肽(T-20)的人类免疫缺陷病毒1型突变体的相对复制适应性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Resistance to enfuvirtide (ENF; T-20), a fusion inhibitor of human immunodeficiency virus type 1 (HIV-1), is conferred by mutations in the first heptad repeat of the gp41 ectodomain. The replicative fitness of recombinant viruses carrying ENF resistance mutations was studied in growth competition assays. ENF resistance mutations, selected in vitro or in vivo, were introduced into the env gene of HIV-1NL4-3 by site-directed mutagenesis and expressed in HIV-1 recombinants carrying sequence tags in nef. The doubling time of ENF-resistant viruses was highly correlated with decreasing ENF susceptibility (R2 = 0.859; P < 0.001). Initial fitness experiments focused on mutants identified by in vitro selection in the presence of ENF (L. T. Rimsky, D. C. Shugars, and T. J. Matthews, J. Virol. 72:986-993, 1998). In the absence of drug, these mutants displayed reduced fitness compared to wild-type virus with a relative order of fitness of wild type > I37T > V38 M > D36S/V38 M; this order was reversed in the presence of ENF. Likewise, recombinant viruses carrying ENF resistance mutations selected in vivo displayed reduced fitness in the absence of ENF with a relative order of wild type > N42T > V38A > N42T/N43K ≈ N42T/N43S > V38A/N42D ≈ V38A/N42T. Fitness and ENF susceptibility were inversely correlated (r = −0.988; P < 0.001). Similar results were obtained with recombinants expressing molecularly cloned full-length env genes obtained from patient-derived HIV-1 isolates before and after ENF treatment. Further studies are needed to determine whether the reduced fitness of ENF-resistant viruses alters their pathogenicity in vivo.
机译:对恩夫韦肽(ENF; T-20)(一种人类免疫缺陷病毒1型(HIV-1)的融合抑制剂)的抗药性是由gp41胞外域的第一个七肽重复序列中的突变赋予的。在生长竞争试验中研究了携带ENF抗性突变的重组病毒的复制适应性。通过定点诱变将体外或体内选择的ENF抗性突变引入HIV-1NL4-3的env基因,并在带有nef序列标签的HIV-1重组体中表达。 ENF耐药病毒的倍增时间与ENF敏感性降低相关(R 2 = 0.859; P <0.001)。最初的适应性实验集中于在ENF存在下通过体外选择鉴定出的突变体(L. T. Rimsky,D. C. Shugars和T. J. Matthews,J. Virol。72:986-993,1998)。在没有药物的情况下,与野生型病毒相比,这些突变体的适应性降低,其适应性相对顺序为:野生型> I37T> V38 M> D36S / V38 M;在ENF的存在下,此顺序被颠倒了。同样,在体内选择的带有ENF抗性突变的重组病毒在缺乏ENF的情况下显示出适应性降低,其相对顺序为野生型> N42T> V38A> N42T / N43K≈N42T / N43S> V38A / N42D≈V38A / N42T。适应度和ENF敏感性呈负相关(r = -0.988; P <0.001)。使用表达分子克隆的全长env基因的重组体,从ENF治疗前后从患者来源的HIV-1分离株中获得了相似的结果。需要进行进一步的研究来确定抗ENF病毒的适应性降低是否会改变其体内致病性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号